Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
abacavir + lamivudine + dolutegravir
- Development stage
- Phase 4
- Lead developer
- ViiV Healthcare
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
This drug is a fixed-dose combination of three antiretroviral agents—abacavir, lamivudine, and dolutegravir—formulated as an oral dissolvable strip (ODS) by Oak Therapeutics. Abacavir and lamivudine are nucleoside reverse transcriptase inhibitors (NRTIs) that act as chain terminators to block the conversion of viral RNA into DNA. Dolutegravir is an integrase strand transfer inhibitor (INSTI) that prevents the integration of viral DNA into the host cell genome. This ODS formulation is designed to improve treatment adherence and ease of administration, particularly for pediatric populations or patients with dysphagia. It is currently in advanced preclinical development for the treatment of HIV infection.
- Brand names
- TriumeqTriumeq PD
- Other names
- Abacavir-Lamivudine-Dolutegravir ODS
02
Targets
Integrase allosteric pocket (HIV)Human immunodeficiency virus type 1 reverse transcriptase
Beyond the preview
Go deeper on abacavir + lamivudine + dolutegravir.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on abacavir + lamivudine + dolutegravir.